Wall Street brokerages expect Novartis AG (NYSE:NVS) to post earnings per share (EPS) of $1.25 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Novartis AG’s earnings. The lowest EPS estimate is $1.24 and the highest is $1.25. Novartis AG reported earnings per share of $1.23 in the same quarter last year, which would suggest a positive year-over-year growth rate of 1.6%. The firm is expected to issue its next earnings report before the market opens on Tuesday, October 24th.
On average, analysts expect that Novartis AG will report full-year earnings of $4.76 per share for the current financial year, with EPS estimates ranging from $4.61 to $4.85. For the next year, analysts forecast that the company will post earnings of $5.05 per share, with EPS estimates ranging from $4.27 to $5.29. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that cover Novartis AG.
Novartis AG (NYSE:NVS) last released its earnings results on Tuesday, July 18th. The company reported $1.22 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.16 by $0.06. The firm had revenue of $12.24 billion for the quarter, compared to analysts’ expectations of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The business’s quarterly revenue was down 1.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.23 EPS.
NVS has been the subject of several recent analyst reports. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Novartis AG in a research note on Thursday, June 22nd. Barclays PLC raised Novartis AG from an “underweight” rating to an “equal weight” rating in a research note on Thursday, June 22nd. Leerink Swann reaffirmed a “market perform” rating and set a $83.00 target price on shares of Novartis AG in a research note on Thursday, June 22nd. Credit Suisse Group cut Novartis AG from a “neutral” rating to an “underperform” rating and set a $82.25 target price for the company. in a research note on Wednesday, July 5th. Finally, Zacks Investment Research cut Novartis AG from a “hold” rating to a “sell” rating in a research note on Monday, July 10th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $84.13.
COPYRIGHT VIOLATION NOTICE: “$1.25 EPS Expected for Novartis AG (NVS) This Quarter” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.dispatchtribunal.com/2017/10/28/1-25-eps-expected-for-novartis-ag-nvs-this-quarter.html.
Large investors have recently made changes to their positions in the business. Westwood Holdings Group Inc. boosted its holdings in Novartis AG by 5.6% in the first quarter. Westwood Holdings Group Inc. now owns 5,405 shares of the company’s stock worth $401,000 after acquiring an additional 285 shares in the last quarter. GFS Advisors LLC boosted its holdings in Novartis AG by 6.5% in the second quarter. GFS Advisors LLC now owns 21,314 shares of the company’s stock worth $1,779,000 after acquiring an additional 1,300 shares in the last quarter. Union Bankshares Corp boosted its holdings in Novartis AG by 0.3% in the second quarter. Union Bankshares Corp now owns 37,521 shares of the company’s stock worth $3,132,000 after acquiring an additional 99 shares in the last quarter. Mechanics Bank Trust Department bought a new position in Novartis AG in the second quarter worth approximately $389,000. Finally, ProVise Management Group LLC boosted its holdings in Novartis AG by 12.2% in the second quarter. ProVise Management Group LLC now owns 85,041 shares of the company’s stock worth $7,099,000 after acquiring an additional 9,227 shares in the last quarter. Institutional investors and hedge funds own 10.93% of the company’s stock.
Shares of Novartis AG (NYSE:NVS) opened at 86.04 on Thursday. Novartis AG has a 1-year low of $66.93 and a 1-year high of $86.90. The firm has a 50-day moving average price of $85.46 and a 200 day moving average price of $82.10. The company has a market cap of $201.58 billion, a PE ratio of 31.41 and a beta of 0.73.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Get a free copy of the Zacks research report on Novartis AG (NVS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.